Canada's YM BioSciences says it halted a Phase III trial of its tesmilifene breast cancer drug when a monitoring board said the drug was unlikely to make a big difference in patient survival. "We are very disappointed by this outcome and will be evaluating the data to understand why tesmilifene did not add a clinical benefit in this trial," the company's CEO said.

Full Story:
The Toronto Star

Related Summaries